Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ: TSHA ) with a Outperform and raises the price target from $12 to $15.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.